Premium
Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion
Author(s) -
Muraoka Masashi,
Oka Tadayuki,
Akamine Shinji,
Tagawa Tsutomu,
Morinaga Masafumi,
Inoue Masao,
Yamayoshi Takatomo,
Hashizume Satoshi,
Matsumoto Keitaro,
Hayashi Tomayoshi,
Nagayasu Takeshi
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20470
Subject(s) - medicine , cytology , malignant pleural effusion , pleural effusion , lung cancer , cisplatin , effusion , surgery , saline , survival rate , pleural cavity , cancer , lung , chemotherapy , pathology
Objectives We evaluate the efficacy and safety of the modified intrapleural cisplatin treatment for lung cancer patients with positive pleural lavage cytology or malignant effusion. Methods The treatment was performed for seven patients with malignant effusion and 18 patents with positive pleural lavage cytology. After pulmonary resection, the pleural cavity was filled with cisplatin with a normal saline solution for 30 min. Complications and survival of the patients were evaluated. Results The chest tube duration were significantly prolonged in the treatment (CDDP) group (5.7 ± 3.6 vs. 2.8 ± 2.6 days). We had one operative death that developed a bronchial fistula; however, the other complications were not severe. The mortality rate was 4% and the morbidity rate was 60%. We experienced two carcinomatous pleuritis in the CDDP group. The median survival time of the CDDP group was 47.0 ± 11.1 months and the 3‐ and 5‐year survival rate was 52.6% and 11.3%, respectively. Conclusions We were able to perform this treatment for these advanced lung cancer patients, which had the preventive effect of carcinomatous pleuritis. This therapy shows the possibility of a treatment that might lead to an improvement in the prognosis of these patients, without causing severe complications. J. Surg. Oncol. 2006;93: 323–329. © 2006 Wiley‐Liss, Inc.